HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
申请人:Schmidt Fanny
公开号:US20110118270A1
公开(公告)日:2011-05-19
The present invention relates to compounds of Formula (I) below, to their pharmaceutically acceptable salts and to their isomers or mixtures of isomers: HetAr—X—CHR
1
R
2
(I) in which: -HetAr represents a group chosen from: —X represents a linear, saturated or unsaturated, hydrocarbon-based chain comprising from 8 to 22 carbon atoms, optionally interrupted by an —NH— or —NH—CO— group, —R
1
represents a hydrogen atom or an —OH, —O(C
1
-C
6
)alkyl, —OCO((C
1
-C
6
)alkyl), —OSO
2
((C
1
-C
6
)alkyl) or —OSO
3
H group, and —R
2
represents a hydrogen atom or a (C
2
-C
6
)alkynyl, (C
2
-C
6
)alkenyl or (C
3
-C
6
)cycloalkyl group. The present invention also relates to a process for preparing the compounds of Formula (I), and also to the use thereof, especially in the treatment of neurodegenerative diseases.
本发明涉及以下化合物的化学式(I),其药学上可接受的盐以及它们的异构体或异构体混合物:HetAr—X—CHR1R2(I)其中:-HetAr代表从中选择的一个基团:-X代表由8到22个碳原子组成的线性、饱和或不饱和的基于碳的链,可选地被一个—NH—或—NH—CO—基团中断,-R1代表氢原子或—OH,—O(C1-C6)烷基,—OCO((C1-C6)烷基),—OSO2((C1-C6)烷基)或—OSO3H基团,-R2代表氢原子或(C2-C6)炔基,(C2-C6)烯基或(C3-C6)环烷基基团。本发明还涉及一种制备化学式(I)化合物的方法,以及其用途,特别是在治疗神经退行性疾病方面。